News Biofrontera AG

Equities

B8F

DE0006046113

Delayed Xetra Other stock markets 11:36:00 2024-04-22 am EDT			5-day change	1st Jan Change
0.346 ^EUR	+10.90%		+1.76%	-13.72%

Mar. 11	Biofrontera Files Prospectus for Potential Secondary Stock Offerings	MT
Mar. 05	Medicus Pharma Names COO	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biofrontera Files Prospectus for Potential Secondary Stock Offerings	Mar. 11	MT
Medicus Pharma Names COO	Mar. 05	MT
BIOFRONTERA AG ANNOUNCES REVISED STRATEGY	Feb. 21	AQ
BIOFRONTERA AG, BIOFRONTERA TRANSFERS CLINICAL RESEARCH TO THE U.S.	Feb. 21	AQ
Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $8.9M, vs. Street Est of $8.4M	Nov. 09	MT
Biofrontera Licensor Gets FDA Approval for New Formulation of Ameluz to Treat Actinic Keratosis	23-10-10	MT
Biofrontera Says Sun Pharmaceutical Alleging Breach of Contract In Lawsuit	23-10-03	DJ
Biofrontera AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
Biofrontera Says Skin Disease Therapy Was Well-Tolerated in Phase 1 Safety Trial	23-08-28	MT
Earnings Flash (BFRI) BIOFRONTERA Reports Q2 Revenue $5.8M	23-08-11	MT
Biofrontera Completes Patient Enrollment in Skin Cancer Treatment Study	23-08-10	MT
Top Premarket Decliners	23-07-21	MT
Biofrontera Launches Novel Belixos Active Care	23-07-05	CI
Biofrontera to Effect 1-for-20 Reverse Stock Split	23-07-03	MT
Wall Street Set to Open Lower; Housing Starts Rise More Than Expected	23-06-20	MT
Transcript : Biofrontera AG, Q1 2023 Earnings Call, May 31, 2023	23-05-31
Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
Biofrontera AG Completes Patient Recruitment of Ameluz Phase I Trial	23-05-17	CI
Biofrontera Says it Obtained US Patent for New Photodynamic Therapy Protocol	23-05-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Biofrontera AG

Equities

B8F

DE0006046113

Summary

Filters